Spero Therapeutics Executive Executes Automatic Stock Sale Amid Strong Financial Turnaround
Esther Rajavelu, who holds the concurrent roles of Chief Executive Officer, Chief Financial Officer, and Chief Business Officer at Spero Therapeutics, Inc. (NASDAQ:SPRO), has completed a transaction involving the sale of 25,240 shares of common stock. The transaction occurred on May 4, 2026, with the shares being sold at a price point of $2.51 per …